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Abstract. v-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog (KRAS) genotyping is required prior to anti-epidermal 
growth factor receptor monoclonal antibody therapy adminis-
tered in cases of metastatic colorectal carcinoma (CRC). Thus, 
KRAS mutation screening is required for patient management. 
The present study reported the experience of KRAS/v-raf 
murine sarcoma viral oncogene homolog B1 (BRAF) muta-
tional screening on synchronous CRC pairs from 26 patients, 
which were defined as index lesions (ILs) and concurrent 
lesions (CLs) on the basis of tumor grade and dimension and 
their respective lymph node and distant metastases. Overall, 
KRAS mutations were present in 38.4% of patients, whereas 
BRAF mutations were present at a frequency of 11.5%. The 
genotyping of paired synchronous carcinomas indicated that 
11 patients (42.3%) exhibited discordant KRAS mutational 
statuses in terms of the presence of a mutation in only one 
lesion of the pair or of two different mutations harbored by 
each lesion. BRAF mutations were present in the synchro-
nous tumors of two cases, whereas in two other cases, only 
the IL or CL harbored mutant BRAF. Overall, the mutational 
statuses of distant and lymph node metastases confirm the 
genetic heterogeneity of synchronous primary tumors. These 
results highlighted the fact that adequate sampling and 
comprehensive testing, when feasible, is likely to optimize the 
decision-making process for treatment approaches, even in the 
relatively rare event of multiple synchronous lesions.
Introduction
Two monoclonal antibodies, cetuximab and panitumumab, 
which target the epidermal growth factor receptor (EGFR), 
were approved in Europe and the United States for the treat-
ment of metastatic colorectal carcinoma (CRC) in 2004 
and 2007, respectively. Subsequently, somatic gain-of-function 
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) 
[and v-raf murine sarcoma viral oncogene homolog B1 
(BRAF)] mutations have been identified as reliable and strong 
negative predictors for the response to anti-EGFR treatment 
in CRC (1-6). These specifically include point mutations 
located in codons 12 and 13, which represent ~98% of all 
KRAS mutations in CRC. Based on these observations, the 
European Medicines Agency has curtailed the application 
of palliative cetuximab and panitumumab therapies for the 
treatment of CRC depending on the KRAS wild-type status 
of the tumor tissue, regardless of whether the antibodies are 
applied in combination with conventional chemotherapy or as 
single agents. BRAF, which is downstream from KRAS in the 
mitogen-activated protein kinase pathway, is subject to acti-
vating mutations that facilitate the development of resistance 
to EGFR-targeted monoclonal antibody treatments (7,8).
Several assays for KRAS and BRAF mutations have been 
developed that involve DNA extraction from a single tumor 
tissue block, followed by a mutation-specific, polymerase 
chain reaction (PCR)-based assay or the sequencing of the 
relevant codons. The selection of the tissue blocks for analysis 
is of clinical relevance for the following reasons: i) The tissue 
sampled for genotyping may contain a small population of 
malignant cells and a large population of stromal and inflam-
matory cells; ii) the potential genetic heterogeneity of the tumor 
tissues in terms of KRAS and/or BRAF mutational status; and 
iii) the genetic heterogeneity of multiple types of colorectal 
cancer may result from one or both of the above-mentioned 
circumstances or from an independent tumor origin. Thus, 
investigations that assess the genomic alterations and degrees 
of similarity or differences in multiple types of synchronous 
cancer may provide insight into more opportune treatments in 
the presence of multiple neoplasms. (9-14)
Multiple primary carcinomas often occur in the large 
intestine, and the time to malignant transformation is variable. 
Synchronous carcinomas (SC) are defined as two or more 
primary carcinomas that coexist at the time of diagnosis or 
that are diagnosed within the same six-month period. SCs 
exhibit an incidence of 3-5% and a poorer prognosis, with a 
significantly increased risk of distant metastases compared 
with solitary CRCs. Although, the prognostic significance of 
cancer synchronicity remains unclear (15-18).
From a molecular standpoint, the theoretical basis of 
‘Colorectal Adenoma and Cancer Divergence’ was previously 
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proposed by Tsao et al in 1999 (19). Recently, Balschun et al 
analyzed the genotypes of the KRAS, neuroblastoma RAS viral 
(v-ras) oncogene homolog, phosphatidylinositol-4,5-bispho-
sphate 3-kinase, catalytic subunit α (PIK3CA) exon 20 and 
BRAF genes in synchronous and metachronous primary CRCs 
and reported a certain grade of heterogeneity in synchronous 
CRC (SCRC) patients (65%). The study further discussed the 
diagnostic and therapeutic implications of these observations, 
recommending ‘that therapy should be tailored by the geno-
type of the lesion to be treated’ (20).
The present study investigated the frequency and distribu-
tion of KRAS and BRAF mutations in primary tumors and the 
lymph node and distant metastases of 26 patients with SCRCs 
using highly sensitive and specific methods, both in terms of 
sample handling and mutational analysis.
Materials and methods
Patients and samples. In total, 26 patients with SCRC were 
selected from a consecutive series of 500 cases derived from 
the patient files of Pisa University Hospital (Pisa, Italy) between 
January, 2006 and March, 2010. The study was approved by 
the Institutional Review Board of the University of Pisa, (Pisa, 
Italy). All patients provided their informed consent.
All the cases were retrospectively reviewed by two patholo-
gists and the tumor stages were determined according to the 
TNM classification (TNM Classification of Malignant Tumors, 
International Union Against Cancer, 7th edition) (21).
All the selected patients presented with two adenocarci-
nomas that were grossly, unequivocally separated by normal 
colorectal mucosa at the initial diagnosis of the CRC. The 
average distance between the two tumors was 25.11±2.2 cm 
(minimum, 1 cm; maximum, 64 cm). Among the carcinomas, 
the index lesions (ILs) were defined as the tumors that were the 
most pathologically advanced or the largest, whereas the other 
lesions were designated as the concurrent lesions (CLs) (9,10). 
Clinicopathological characteristics of the analyzed SCs are 
summarized in Table I.
Lymph node metastases were reported in 18 patients, of 
which eight also presented with distant metastases. One patient 
presented only with distant metastases. In the case of multiple 
lymph node and/or distant metastases, each reported and/or 
available metastatic node or distant metastasis was analyzed.
Microdissect ion and DNA extraction. A total of 
77 formalin‑fixed, paraffin‑embedded (FFPE) tissues were 
collected and serially cut into four 10-µm thick sections. The 
last section was stained with hematoxylin-eosin and the area 
of each tumor was delineated by a pathologist. The following 
samples were analyzed in further detail: 26 ILs; 26 CLs; 
17 lymph node metastases; and 8 distant metastases.
Next, the tumor cells were manually microdissected from 
three unstained sections, transferred into 180 µl ATL buffer 
and digested with 20 µl proteinase K overnight at 56˚C. DNA 
isolation was performed according to the FFPE tissue instruc-
tions recommended by the QIAamp DNA Mini kit (Qiagen, 
Valencia, CA, USA).
The nucleic acids were eluted in 40 µl AE buffer and the 
DNA content was measured using a NanoDrop-1000 spectro-
photometer (Thermo Fisher Scientific, Waltham, MA, USA).
Detection of KRAS and BRAF mutations by pyrosequencing. 
A total of 5 µl genomic DNA (20 ng/µl) was amplified using 
anti-EGFR Moab response® (KRAS and BRAF status) confor-
mité Européene-in vitro diagnostic (CE-IVD)-marked 
kits (Diatech Pharmacogenetics Srl, Jesi, Italy) on a 
Rotor-GeneTM 6000 (Corbett Research, Sydney, Australia), 
according to the manufacturer's instructions. The resulting PCR 
product was immobilized onto magnetic streptavidin-coated 
beads (Diatech Pharmacogenetics Srl) via biotin/streptavidin 
interaction. The bead/DNA complexes were then washed 
and added to 1.65 pmol pyrosequencing primer, which 
was included in the same kit. The primed, single-stranded 
DNA templates were transferred to a microtiter plate-based 
PSQ HS 96A Pyrosequencer (Biotage AB, Uppsala, Sweden) 
in which the real-time sequencing of the sequence surrounding 
codons 12 and 13 of KRAS and codon 600 of BRAF was 
performed using PyroMark Gold Q96 reagents (Qiagen) on 
a PyroMarkTM Q96 ID instrument (Biotage AB). The results 
were analyzed using PyroMark Q24 1.0.9 software.
Results
KRAS and BRAF genotyping. Overall, KRAS mutations were 
detected in 14 of the 26 SC patients (53.8%), whereas BRAF 
mutations were found in only four patients (15.4%).
KRAS/BRAF mutational status of the ILs. A total of 10 KRAS 
mutations were detected among the 26 ILs, with a mutation rate 
of 38.5%. In particular, 8 of the 10 mutations were in KRAS 
codon 12, whereas two were in codon 13. In total, three ILs 
(11.5%) harbored BRAF mutations (Table II).
KRAS/BRAF mutational status of the CLs. KRAS mutations 
were detected in 10 (38.5%) of the CLs; seven were located in 
KRAS codon 12 and three were in codon 13. In total, three CLs 
(11.5%) harbored BRAF mutations (Table II).
Table I. Clinicopathological features of the SCRC pairs.
Variables IL CL
Lesions, n 26 26
Average size, cm (SEM) 4.91 (±1) 3 (±1)
Grade, n  
  Moderate 18 20
  Poor   8   6
% of mucinous component, n  
  0 15 16
  <50   7   8
  ≥50   4   2
Wall penetration, n  
  pT2   5 20
  pT3 19   6
  pT4b   2   0
SCRC, synchronous colorectal carcinoma; IL, index lesion; CL, 
concurrent lesion.
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KRAS/BRAF mutational status of the lymph node and distant 
metastases. A total of six KRAS mutations were found and 
analyzed in the lymph node, with four in the distant metas-
tases. By contrast, three BRAF mutations were found in the 
lymph node, with one in the distant metastases (Table II).
Distribution of KRAS/BRAF mutations among the ILs and CLs. 
KRAS mutational status. Among the 26 SCs tested, a total of 
15 cases (57.7%) exhibited the same genotype (genetically homo-
geneous), whereas, 11 (42.3%) exhibited a different genotype 
(genetically heterogeneous). In total, 12 of the 15 homogeneous 
cases harbored wild-type KRAS and two cases exhibited the same 
mutation in each tumor. Among the KRAS heterogeneous cases, 
eight exhibited a discordant KRAS mutational status between the 
two lesions, and three harbored a different mutation (Table II).
BRAF mutational status. In total, 24 cases were genetically 
homogeneous, whereas two (7.7%) were heterogeneous. 
Among the homogeneous pairs, two harbored the V600E 
mutation in the two lesions and 22 harbored wild-type 
BRAF (Table II).
Distribution of KRAS/BRAF mutations between the ILs, CLs 
and distant and lymph node metastases. Genotype concor-
dance between the ILs and relative distant metastases was 
found in all the analyzed cases, whereas in five patients, the 
CLs exhibited a different KRAS mutational status compared 
with that of the distant metastases (Table II). A single patient 
with a mutant BRAF-harboring distant metastasis harbored 
the same mutation as in the IL, but not the CL (Table II).
The lymph node metastasis KRAS genotype corresponded 
with that of the IL in 12 out of 14 patients. In one patient, two 
lymph node metastases were found that harbored two different 
KRAS mutations, which corresponded with that of the IL 
and CL, respectively. In one patient, lymph node metastasis 
was found harboring the same KRAS mutation as that in the 
CL (Table II).
Discussion
KRAS genotyping is required prior to anti-EGFR monoclonal 
antibody therapy that is administered in cases of metastatic 
CRC. Thus, KRAS mutation screening is required for patient 
Table II. KRAS and BRAF genotype (n=26).
 KRAS BRAF
 ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
Patient IL CL LMet L2Met DMet IL CL LMet L2Met DMet
  1 G12A G12S G12A G12S G12A WT WT WT WT WT
  2 G12C G12C NP  G12C WT WT NP  WT
  3 G12C WT G12C WT  WT WT WT WT 
  5 G12D G12D NP   WT WT NP  
  4 G12D WT NP  G12D WT V600E NP  WT
  6 G12S WT WT   WT WT WT  
  7 G12V G12D    WT WT   
  8 G12V G13D G12V  G12V WT WT WT  WT
  9 G13D G13D G13D   WT WT WT  
10 G13D WT G13D   WT WT WT  
11 WT G12A WT   WT WT WT  
12 WT G12D    WT WT   
13 WT G12D WT  WT WT WT WT  WT
18 WT G13D WT  WT V600E WT V600E  V600E
19 WT WT   WT WT WT   WT
20 WT WT    WT WT   
14 WT WT    WT WT   
15 WT WT    WT WT   
16 WT WT    WT WT   
17 WT WT WT  WT WT WT WT  WT
21 WT WT WT   WT WT WT  
22 WT WT WT   WT WT WT  
23 WT WT NP  NP WT WT NP  NP
24 WT WT WT   V600E V600E V600E  
25 WT WT WT WT  V600E V600E V600E WT 
26 WT WT    WT WT   
KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; BRAF, v-raf murine sarcoma viral oncogene homolog B1; IL, index lesion; CL, 
concurrent lesion; LMet, lymph node metastases; DMet, distant metastases; WT, wild‑type; NP, not performed.
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management (1-6). Screening of the BRAF mutational status 
is not yet a prerequisite for the administration of anti-EGFR 
treatments, but may become required by clinicians, given its 
strong prognostic significance (7,22).
The current study reported the experience of KRAS/BRAF 
mutational screening performed on 26 FFPE SC pairs and 
their respective lymph node and distant metastases.
KRAS mutations were present in 38.5% of the ILs and 
CLs, whereas BRAF mutations were present at a frequency of 
11.5% in the ILs and CLs.
The KRAS and BRAF mutational rates for the ILs and CLs 
are in line with those previously reported by Balschun et al in 
synchronous and metasynchronous CRCs (20). In the present 
series, the genotyping of paired SC tumors indicated that 
11 patients (42.3%) exhibited discordant KRAS mutational 
statuses in terms of the presence of a mutation in only one lesion 
of the pair or of two different mutations harbored by each lesion. 
By contrast, 15 patients exhibited the same KRAS genotype; 
three patients harbored the same KRAS mutation as in the IL 
and CL, whereas 12 harbored wild-type KRAS. BRAF muta-
tions were present in the ILs and CLs of two cases, whereas in 
two other cases, only the IL or CL harbored mutant BRAF.
Intratumorally, KRAS and BRAF mutations are mutually 
exclusive. No single tumor was identified that harbored KRAS 
and BRAF mutations. Notably, KRAS and BRAF mutations 
were not mutually exclusive when considering SC pairs. One 
patient was identified with a mutant KRAS‑harboring IL with 
a mutant BRAF-harboring CL and an additional patient exhib-
ited the inverse distribution of these mutations. Furthermore, 
the KRAS and BRAF genotype was not found to correlate with 
increased T-status or grade of the carcinomas.
In the current series, distant metastatic lesions were 
reported in nine patients, of which tissue samples for geno-
typing were available from eight. Lymph node metastases were 
reported in 18 patients, of which tissue samples were available 
from 14 (Table II). Overall, the mutational statuses of distant 
and lymph node metastases confirm the genetic heterogeneity 
of synchronous primary tumors.
In particular, the present study found that the genotype of 
the distant metastases is always the same as that of the IL, 
Figure 1. Schematic representation of hematoxylin and eosin-stained sections and relative pyrograms of two patients. The upper lane presents the KRAS 
analysis, the middle lane presents the BRAF analysis and the lower lane presents the histology in patients 1 and 18 (magnification, x20). (a) Patient 1 index 
lesion: moderately differentiated adenocarcinoma. (b) Patient 1 concurrent lesion: differentiated adenocarcinoma. (c and d) Patient 1 regional lymphnode: 
metastases of adenocarcinoma. (e) Patient 1 omental lesion: metastases of adenocarcinoma. (f) Patient 18 index lesion: moderately differentiated adeno-
carcinoma. (g) Patient 18 concurrent lesion: moderately differentiated adenocarcinoma. (h) Patient 18 regional lymphnode: metastasis of adenocarcinoma. 
(i) Patient 18 omental lesion: metastasis of adenocarcinomas. KRAS: G12A, pyrogram trace showing a G to C mutation in position 2 of codon 12; G12S, 
pyrogram trace showing a G to A mutation in position 1 of codon 12; G13D, pyrogram trace showing G to A mutation in position 2 of codon 13. BRAF: V600E, 
pyrogram trace showing a T to A mutation in position 2 of codon 600. Arrows identify the sequence alterations. WT pyrogram trace revelas a normal genotype. 
Light blue and orange areas indicate the variable position. KRAS, v Ki ras2 Kirsten rat sarcoma viral oncogene homolog; BRAF, v raf murine sarcoma viral 
oncogene homolog B1; IL, index lesion; CL, concurrent lesion; LMet, lymph node metastases; DMet, distant metastases; WT, wild type.
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and in three cases, the same as that of the CL. Among the 
five heterogeneous cases, three harbored different mutations 
in the IL and metastasis compared with the CL. Notably, in 
two patients, the distant metastases and IL were wild-type, 
whereas the CL harbored mutant KRAS.
Consequently, the genetic analysis of metastatic SCs may fail 
in predictive value due to the heterogeneous KRAS mutational 
status of the IL and CL. Taken together, the results of present 
study confirmed the genetic heterogeneity of KRAS and BRAF 
that was previously reported by Balschun et al. This previous 
study suggested that an examination of an arbitrarily selected 
archival tumor sample may carry the risk of a non-repre-
sentative genotype and thus, of inadequate treatment (20). 
These observations partially contradict the observations 
by Baldus et al (23) and Voutsina et al (24). In particular, 
Baldus et al studied KRAS, BRAF and PIK3CA distribution 
patterns in primary tumors and corresponding metastases 
and suggested that from a diagnostic perspective, genotyping 
‘should preferentially be done on samples of primary tumors 
or distant metastases, whereas lymph node metastases seem 
to be a less appropriate tool’ (23). In studying KRAS, PIK3CA 
and BRAF mutations together with MET and PTEN expression 
in colorectal primary tumors and corresponding metastases, 
Voutsina et al more recently concluded that metastatic lesions 
are the most appropriate tissues to analyze in order to determine 
the appropriate targeted therapies in metastatic CRC. This is 
despite discordance between the primary CRC tumors and 
associated metastases in terms of the biomarkers examined, 
with the exception of BRAF mutations (24).
From a practical perspective, these results highlight the 
requirement for a tight cooperation between oncologists 
and pathologists when assessing KRAS and BRAF muta-
tional status for clinical purposes. Adequate sampling and 
comprehensive testing, when feasible, is likely to optimize the 
decision-making process for treatment approaches, even in the 
relatively rare event of multiple synchronous lesions.
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